We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
Current production processes, in which host mammalian cells are used to generate
lentivirus, are inefficient, resulting in low yields, lack of scalability, and high biomanufacturing costs.
With clinical trials and FDA approval of T-cell immunotherapy, efficient lentiviral production processes
appropriate for large scale manufacturing are needed.
The aim of the NIIMBL-funded project was to provide the industry with a lentivirus production process that yields large quantities of highly potent vector with fast facility turnaround times.
Improved viral vector production process yield, processing times, and measurement accuracy
Development of a platform process to mitigate lentiviral vector supply shortages for cell and gene therapy
Ghosh, R., Koley, S., Gopal, S., Rodrigues, A. L., Dordick, J. S., & Cramer, S. M. (2022). Evaluation of lentiviral vector stability and development of ion exchange purification processes. Biotechnology Progress, 38(6). https://doi.org/10.1002/btpr.3286
Login to the NIIMBL member portal to access more, including:
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
University of Massachusetts Medical School
Artemis Biosystems Inc.
Cogent Biosciences
Johns Hopkins University
Massachusetts Life Sciences Center
Rensselaer Polytechnic Institute
Repligen Corporation
